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Abstract
Background: Lactobacillus mucosae DPC 6426 has previously demonstrated potentially cardio-protective properties,
in the form of dyslipidaemia and hypercholesterolemia correction in an apolipoprotein-E deficient mouse model.
This study aims to characterise the manner in which this microbe may modulate host bile pool composition and
immune response, in the context of cardiovascular disease. Lactobacillus mucosae DPC 6426 was assessed for bile
salt hydrolase activity and specificity. The microbe was compared against several other enteric strains of the same
species, as well as a confirmed bile salt hydrolase-active strain, Lactobacillus reuteri APC 2587.
Results: Quantitative bile salt hydrolase assays revealed that enzymatic extracts from Lactobacillus reuteri APC 2587
and Lactobacillus mucosae DPC 6426 demonstrate the greatest activity in vitro. Bile acid profiling of porcine and
murine bile following incubation with Lactobacillus mucosae DPC 6426 confirmed a preference for hydrolysis of
glyco-conjugated bile acids. In addition, the purified exopolysaccharide and secretome of Lactobacillus mucosae
DPC 6426 were investigated for immunomodulatory capabilities using RAW264.7 macrophages. Gene expression
data revealed that both fractions stimulated increases in interleukin-6 and interleukin-10 gene transcription in the
murine macrophages, while the entire secretome was necessary to increase CD206 transcription. Moreover, the
exopolysaccharide elicited a dose-dependent increase in nitric oxide and interleukin-10 production from RAW264.7
macrophages, concurrent with increased tumour necrosis factor-α secretion at all doses.
Conclusions: This study indicates that Lactobacillus mucosae DPC 6426 modulates both bile pool composition and
immune system tone in a manner which may contribute significantly to the previously identified cardio-protective
phenotype.
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Background
The gut microbiome is a complex ecosystem of diverse
metabolic pathways which is central to the progression
and prevention of host cardiovascular disease (CVD)
and other closely related metabolic dysfunctions such as
obesity and type-2 diabetes [1]. These microorganisms
are capable of contributing specifically to atherogenesis
through a number of pathways, with the potential to
alter gut hormone signalling, bile and lipid metabolism
and inflammatory status [2]. Conversely, under the cor-
rect environmental conditions such as favourable nutri-
tion, certain members of the gut microbiome can
actively counteract the factors which contribute to
atherogenesis [3].
In clinical terms, plasma lipid profiles are among the
most important predictors for cardiovascular dysfunc-
tion. The sizeable human population which are classified
as dyslipidaemic rely heavily on statins for disease pre-
vention and management. However, recent insight has
demonstrated that certain members of the enteric
microbiota can also have beneficial effects on host lipid
metabolism, with significant knock-on implications for
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cardiovascular function [4]. Lactobacillus mucosae DPC
6426 has been shown to attenuate the dyslipidaemia and
hypercholesterolemia observed in apolipoprotein-E defi-
cient mice maintained on a high-fat/cholesterol diet [5],
and may have application as a potential therapy or ad-
junct to pharmaceutical CVD intervention. One mech-
anism through which gut microbes are known to impact
on host lipid profile is through a set of enzymes, termed
bile salt hydrolases (BSH), which function in deconju-
gating bile salt to bile acid (BA) [6]. These enzymes are
produced primarily as a defence against the harsh en-
teric environment and act in cleaving the amino group
off a BA, rendering the molecule amenable to further
degradation by other bacterial enzymes, such as
7-α-dehydroxylases [7–9]. This process reduces BA re-
absorption in the ileum and in turn can up-regulate de
novo synthesis of BA, of which cholesterol is a major
component. This effect is the result of the suppression
of the ileal farnesoid X receptor-fibroblast growth factor
(FXR-FGF)15/19 axis, which impacts through the hep-
atocyte membrane FGFR4/ß-klotho complex primarily
on CYP7A1-expression downstream in the cascade; ul-
timately, improving the host lipid profile and metabolic
health [10, 11], potentially leading to a reduced risk of
CVD.
A second means through which gut bacteria may alter
host lipid metabolism is through expression of complex
polysaccharides, termed exopolysaccharides (EPS). A
previous study from our group has demonstrated the
ability of Lactobacillus mucosae DPC 6426 – a natural
EPS+ strain – and a recombinant EPS+Lactobacillus spp.
to alter lipid metabolism in an apolipoprotein-E deficient
mouse model [5]. In this study, Lactobacillus paracasei
NFBC 338 was transformed to express the glycosyltrans-
ferase gene of Pediococcus parvulus 2.6 in the pNZ44
plasmid. This strain was compared against its EPS− iso-
genic control (solely expressing the empty plasmid vec-
tor) for their effects on host lipid profile. The EPS+
strains demonstrated the ability to significantly reduce
host serum cholesterol and triglyceride levels by up
to 50 and 25%, respectively, while also modulating
the effects of several proinflammatory and proath-
erogenic factors - however the mechanisms under-
lying these improvements have not been entirely
determined.
Inflammation plays a central role in the development
and progression of several metabolic disease states [12],
including those which lead to atherosclerosis [13]. One
major contributor to this process is inflammatory lipo-
polysaccharide (LPS)-mediated Toll-like receptor (TLR)4
signalling, a process which has a substantial negative im-
pact on atheroprotective reverse cholesterol transport.
TLR4-activation suppresses liver X receptor expression
[14, 15], which in turn results in increased low-density
lipoprotein receptor, very low-density lipoprotein receptor
and adiponectin receptor-2 transcription [16] – ultimately
promoting lipid accumulation in macrophages, which re-
sults in foam cell formation and atherogenesis. Con-
versely, immunological pathways exist through which the
gut microbiome may inhibit inflammation and other im-
munological pathologies associated with CVD and meta-
bolic dysfunction. Interleukin (IL)-10, a potent
anti-inflammatory molecule which can be stimulated by
commensal and probiotic metabolites such as EPS [17],
has displayed a protective role in the development of ath-
erosclerosis. In addition, several prebiotics [18] and pro-
biotics [19] have previously displayed considerable
potential to attenuate host inflammation in a useful man-
ner and it is likely that such an effect will have implica-
tions for metabolic health and, in turn, CVD risk. Indeed,
co-culture of human macrophages with the koumiss-
derived Lactobacillus helveticus NS8 has been demon-
strated to induce IL-10 secretion and attenuate the syn-
thetic inflammation created in a murine model of colitis
[20]. Moreover, a kimchi-isolated strain of Lactobacillus
brevis has also been found to impact beneficially upon the
development of experimental colitis in mice through in-
creased polarization of alternatively activated macro-
phage and inhibition of the nuclear factor-κB (NF-κB)
pathway [21]. Interestingly, the application of a
heat-killed Lactobacillus plantarum to an animal model
of obesity and insulin resistance revealed an immuno-
modulatory and lipid metabolism altering effect of the
strain [22]. This suggests that such attributes may be
mediated by a structural molecule, such as EPS. This
study aims to assess various properties of Lactobacillus
mucosae DPC 6426 which might mechanistically ad-
dress the ability of the strain to exhibit cardio-protect-
ive effects as observed in mice studies.
Results
Lactobacillus mucosae DPC 6426 secretome and EPS
induce macrophage phenotypes that share features of
both classically and alternatively activated macrophages
Recently, it was posited that ingestion of Lb. mucosae
DPC 6426 alters lipid metabolism due to the production
of a complex polysaccharide [5]. To investigate the ability
of EPS isolated from Lb. mucosae DPC 6426 and the
secretome of Lb. mucosae DPC 6426 to induce macro-
phage polarization – a key factor in the inflammation-
mediated development of atherosclerosis – alterations in
tumor necrosis factor (TNF)-α, inducible nitric oxide syn-
thase (iNOS), CD206, IL-6 and IL-10 gene expression
were analysed in a murine macrophage cell line. Stimula-
tion with LPS/interferon-gamma (IFN-γ) or IL-4 was in-
cluded in each experiment to ensure functional
differentiation into M1 or M2 subtypes, respectively. The
average relative increase in TNF-α and iNOS transcription
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after LPS/IFN-γ treatment was 5-fold and 2.5-fold, re-
spectively, while the average increase in CD206 and Il-10
gene expression after IL-4 treatment was 40-fold and
300-fold, respectively – indicating successful polarization
(data not shown). Neither the secretome nor isolated EPS
from Lb. mucosae DPC 6426 significantly increased gene
expression of the inflammatory cytokine TNF-α (Fig. 1A).
In contrast, relative expression of the iNOS gene, which is
expressed in classically activated macrophages, was in-
creased by both the Lb. mucosae EPS and secretome frac-
tions compared to unstimulated cells (p < 0.01; Fig. 1A).
Interestingly, gene expression for CD206 following stimu-
lation with the secretome of Lb. mucosae DPC 6426 was
significantly increased (p < 0.01), while the isolated EPS
stimulation had no such effect (Fig. 1B). IL-10 gene ex-
pression, a marker of alternatively activated macrophages
was significantly increased following stimulation with both
the secretome and isolated EPS of Lb. mucosae DPC 6426
(p < 0.0001; Fig. 1B). The gene expression for IL-6 was
significantly increased following stimulation with the
secretome (p < 0.01) and EPS (p < 0.0001), compared
to unstimulated macrophages (Fig. 1C). Thus, the Lb.
mucosae secretome and EPS induce macrophage phe-
notypes that share features of both classically and al-
ternatively activated macrophages and in particular
the anti-inflammatory cytokine IL-10.
Macrophage stimulation with EPS induces relatively low
amounts of NO compared to LPS
Stimulation of RAW 264.7 macrophages with 1 μg/ml
EPS did not increase NO production above basal
levels in unstimulated cells (1–2 uM) and 5 μg/ml
EPS increased NO production to approximately 5 uM.
In contrast, stimulation of macrophages with 1 μg/ml
LPS increased NO production to 25–50 μM, which
was only achieved by stimulation with large quantities
(100 μg/ml) of EPS (Fig. 1D). LPS induced NO pro-
duction was moderately increased by addition of 10
μg/ml or more EPS in a dose-dependent fashion.
Stimulation of macrophages with 1μg/ml LPS or low
amounts of EPS (1–10 μg/ml) increased the cellular
metabolic activity whereas the combination of 1μg/ml
LPS with 10 to 100 μg/ml EPS decreased metabolic
activity despite the greater amount of induced NO
production. These results indicate that relatively large
amounts of EPS are required to induce more than 5
uM NO production in unstimulated macrophages.
Lactobacillus mucosae DPC 6426 EPS does not affect
oxidative burst activity
Isolated EPS did not affect the oxidative burst activity in
neutrophils (Additional file 1: Figure S1), and this was
demonstrated with neutrophils differentiated from a
Fig. 1 Lactobacillus mucosae DPC 6426 Macrophage Polarization. Transcription of M1-related markers (a) TNF-α and iNOS, M2-related markers (b)
CD206 and IL-10, as well as (c) IL-6 following 24 h exposure to either the secretome of Lactobacillus mucosae DPC 6426 (SEC) or 10 mg/mL of
isolated EPS. Results for the same markers are also displayed for polarised macrophages. In a separate series of experiments, macrophages were
stimulated with EPS for 24 h with or without additional LPS stimulation after which NO (d) and IL-10 (e) production was measured. In the same cells,
viability was measured using an XTT assay (f). All experiments were conducted three times with duplicate samples. Data are shown as average ± SD,
and were analysed by one-way ANOVA. Differences were considered statistically significant when p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)
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human cell line, as well as with freshly isolated neutro-
phils obtained from healthy volunteers. Moreover, even
in neutrophils activated by PMA, addition of isolated
EPS did not increase the production of reactive oxygen
species (ROS). Again, this result was found for neutro-
phils that were derived from a cell line and freshly iso-
lated neutrophils alike.
Lactobacillus mucosae DPC 6426 is highly BSH-active
Plate assays (Fig. 2) revealed that all strains introduced previ-
ously had some level of BSH activity for glycodeoxycholic
acid (GDCA), while only Lb. mucosae DPC 6418 showed no
apparent deconjugation activity for taurodeoxycholic acid
(TDCA). The largest halo was recorded for Lb. mucosae
DPC 6426 grown on TDCA-supplemented MRS; while the
weakest halo was seen in Lb. mucosae DPC 6418 grown on
GDCA-supplemented MRS. BSH activity assays performed
with standardised protein extracts demonstrated that all
strains bar Lb. mucosae DPC 6418 showed greater affinity to
deconjugate GDCA than TDCA (p < 0.001). Lb. reu-
teri APC 2587 showed the greatest BSH activity for
both TDCA (p < 0.0001) and GDCA (p < 0.0001) at
174 and 395 Umin− 1, respectively. Lb. mucosae DPC
6426 followed closely with 75 and 165 Umin− 1 for
TDCA and GDCA, respectively. Both Lb. mucosae
DPC 6420 and 6425 had similar, but greatly reduced
GDCA BSH activity of ~ 20 Umin− 1, which was still
significantly higher than that of Lb. mucosae DPC
6418 (~ 5 Umin− 1; p < 0.001). Finally, Lb. mucosae
DPC 6420, 6425 and 6418 all demonstrated < 6 U
min− 1 of TDCA BSH activity, which was significantly
lower than that of both Lb. reuteri APC 2587 and Lb.
mucosae DPC 6426 (p < 0.0001).
Lactobacillus mucosae DPC 6426 displays preference for
glyco-conjugated bile acids
Of the 25 BAs quantified in this assay, 21 were found to be
significantly altered in porcine bile following incubation with
Lb. reuteri APC 2587 (Additional file 1: Table S2; p < 0.05).
Of the remaining four unaltered BAs, three were not de-
tected at any level in the porcine bile. Co-incubation of Lb.
reuteri APC 2587 with murine bile resulted in alterations of
13 BAs (p < 0.05), principally primary BAs (pBA) and
tauro-conjugated BAs (TcBA; Fig. 3E). Conversely, incuba-
tion with Lb. mucosae DPC 6426 significantly altered 13 BAs
in porcine bile and just three in murine bile (p < 0.05) – taur-
olithocholic acid (TLCA), deoxycholic acid (DCA) and gly-
cohyodeoxycholic acid (GHDCA). When the bile profiles
were grouped into their subcategories (Fig. 3D/E), it became
clear that Lb. mucosae DPC 6426 favoured glyco-conjugated
BA (GcBA) hydrolysis and, in turn, significantly increased
both pBA and secondary BA (sBA) levels (p < 0.05). Lb. reu-
teri APC 2587 also displayed a greater affinity for GcBA-hy-
drolysis, however, the strain also proved capable of depleting
murine bile TcBA (p < 0.05). Principal component analysis
(PCA) plots of the data demonstrate that both strains altered
porcine and murine bile to such a degree that the data points
cluster distinctly from the untreated bile (Fig. 3A/B).
However, it is apparent that the impact of Lb. mucosae DPC
6426 on the murine bile composition was modest. When
both strains are plotted together, we observe distinct cluster-
ing of samples by treatment, giving further indication that
the two Lactobacillus spp. demonstrate specificity in their
BA hydrolysis activity and distinct substrate preferences.
Discussion
CVD, and the debilitating metabolic dysfunctions
which so often accompany it, are a global problem
with few effective, non-invasive therapies free of ad-
verse side-effects. Moreover, a significant portion of
the at-risk population can be classed as mildly hyper-
cholesterolemic. This cohort has been proven to
benefit significantly from cholesterol-reducing bacter-
ial therapies, without significant adverse events [23,
24]. Lb. mucosae DPC 6426 has demonstrated the
Fig. 2 Bile Salt Hydrolase Activity of Lactobacillus mucosae Strains
Compared to a Bile Deconjugating Lactobacillus reuteri. One unit
of bile salt hydrolase activity is defined here as nmol of amino
acid (taurine or glycine) cleaved from the relevant bile acid per
mg of protein per minute. Taurine and glycine bile salt
hydrolase activity are portrayed with red and black bars,
respectively. Bars represent the means of triplicate experiments
and error bars represent standard deviations. Images depict cell
masses of each strain grown on MRS containing no bile acids
(Control), MRS supplemented with taurodeoxycholic acids (Tauro)
and glycodeoxycholic acid (Glyco). Strains which demonstrate
bile salt hydrolase activity towards a particular bile acid are
shown with a positive sign (+), while lack of activity is shown
with a negative sign (−). Weak activity is indicated by +/−
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ability to attenuate circulating cholesterol accumula-
tion in a murine model of high-fat diet-aggravated
CVD [5]. However, the mechanism through which
this microorganism exerts its cardio-protective effects
has remained unclear to date. In this study, we aimed
to explore two notable metabolic features of the
strain – the EPS and bile-deconjugating enzymes
which it produces – and, ultimately, to determine the
potential implications for host cardiometabolic health.
Classically activated macrophages, defined as the M1
subtype, are characterized by the expression of high
levels of TNF-α, IL-6 and iNOS, and therefore amplify
inflammation. Alternatively activated macrophages,
known as the M2 subtype, promote tissue homeostasis
by releasing IL-10 and transforming growth factor-β and
rely heavily on β-oxidation [25]. The two subsets are
present in human atherosclerotic plaque development
[26, 27], with atherosclerotic lesions being characterized
Fig. 3 Deconjugation Profile of Porcine and Murine Bile Supplemented Culture Media Incubated with Lactobacillus mucosae DPC 6426 or a Bile
Salt Hydrolase Active Lactobacillus reuteri. Principal component analysis (PCA) plots of bile deconjugation profiles of the two most active bile salt
hydrolase strains in this study, Lb. mucosae DPC 6426 and Lb. reuteri APC 2587, are compared against untreated bile (a and b, respectively) and
each other (C). Porcine (d) and murine (e) bile supplemented MRS bile acid profiles untreated (black), following overnight incubation with Lb.
reuteri APC 2587 (dark red) or Lb. mucosae DPC 6426 (light red). Data are divided into primary bile acids (pBA), secondary bile acids (sBA), tauro-
conjugated bile acids (TcBA) and glyco-conjugated bile acids (GcBA). Data were considered statistically significant when p < 0.05 (*) and plots
depict replicates with mean and SEM
Ryan et al. BMC Microbiology           (2019) 19:33 Page 5 of 13
by macrophages with the M1 phenotype. Both the Lb.
mucosae secretome and EPS induced macrophage phe-
notypes share features of both classically and alterna-
tively activated macrophages. A notable feature of EPS
and secretome stimulation of macrophages was the tran-
scription of anti-inflammatory cytokine IL-10 and the
scavenger receptor CD206, which are both characteristic
of anti-inflammatory macrophages. Additionally, we
showed that EPS could increase IL-10 production in LPS
activated macrophages in a dose dependent fashion.
Interestingly, both fractions of Lb mucosae increased
IL-6 expression in macrophages. IL-6 is the most abun-
dant cytokine and has frequently been uncovered in the
context of obesity-associated metabolic disorders [28,
29]. However, it was recently demonstrated that IL-6
may control the maintenance of M2 macrophages [30].
IL-6, similar to IL-10 is a potent inducer of the IL-4/
STAT6 axis which is essential for M2 macrophage
polarization. Thus, IL-6 may exert its effect as a priming
factor for anti-inflammatory IL-4 action in macrophages.
Although iNOS transcription (a marker of M1 pheno-
type) was increased in EPS and secretome stimulated
macrophages, EPS was not a strong inducer of NO at
low concentrations. Furthermore, the EPS of Lb. mu-
cosae DPC 6426 did not induce ROS production in
HL60 cells differentiated into neutrophil-like cells or
freshly isolated neutrophils (Supplementary Fig. 1).
Taken together, these results suggest that Lb. mucosae
DPC 6426 in combination with its secreted metabolites
including the EPS could negatively impact on atherogen-
esis via the effect of its anti-inflammatory activities in
the intestinal lamina propria and mucosal lymphoid tis-
sues. Intestinal immunity has attracted much attention
as a therapeutic target for atherosclerosis and other in-
flammatory diseases [31]. Heightened inflammation in
the intestine is linked to increased epithelial permeability
and increased levels of LPS in the tissues and blood.
Translocation of small numbers of bacteria or bacterial
products such as LPS is now regarded as one important
mechanism causing the low-grade inflammation in the
liver and other tissues [12, 32]. In the lymphoid tissues,
the anti-inflammatory properties of Lb. mucosae DPC
6426 could support the induction of tolerogenic re-
sponses in gut macrophages and dendritic cells support-
ing the integrity of the gut barrier and promoting
induction of regulatory T cells, which have been pro-
posed to be atheroprotective [33].
It is relevant at this point to note that the EPS pro-
duced by Lb. mucosae DPC 6426 is unusual for that of
its genus. In fact, the heteropolysaccharide is reported to
contain a high proportion of mannose residues in
addition to the more common glucose and galactose.
Importantly, mannose residues are more commonly as-
sociated with pathogenic or opportunistic organisms
and, as a result, there are a number of human carbohy-
drate receptors which may initiate an immune response
when faced with such a ligand. Such receptors include,
but are not limited to, DC-SIGN, Dectin-2, MBL-1,
MBL-2, CD206, CD280 and Mincle. For instance, the
cell membranes of yeasts are coated densely with a
mannoprotein-polysaccharide complex which could po-
tentially act on the same receptors as the EPS described
in this study. In the case of yeast, the polysaccharide zy-
mosan is phagocytised following activation of macro-
phage CD206 (mannose receptor), after which internal
TLR2 activation results in increased TNF-α secretion
[34]. It is indeed likely that the unusual structure of the
EPS plays a role in the expression of IL-10 in
macrophages.
BSH activity assays revealed that both Lb. reuteri APC
2587 and Lb. mucosae DPC 6426 protein extracts con-
tained one or more BSH homologues at impactful levels,
while the other three Lb. mucosae displayed only modest
or negligible BSH activity. Lb. mucosae DPC 6418, the
strain which demonstrated the least BSH activity, also
failed to form a full cell mass on plate assays (Fig. 2). This
suggests that it may not actually be adapted to the
bile-rich enteric environment, despite its reported enteric
origin (Additional file 1: Table S1). The BSH activity re-
sults in fact mirror those of the bile profiling, in that Lb.
reuteri APC 2587 had affinity for both GcBA and TcBA
substrates, while Lb. mucosae DPC 6426 displayed similar
GcBA-hydrolysis, but relatively reduced TcBA-hydrolysis.
Several different Lactobacillus spp. have previously been
reported to show a substrate preference towards GcBA
over TcBA-hydrolysis [35, 36].
BAs have emerged as signalling molecules that interact
with specific cellular receptors to regulate host metabol-
ism [2, 37, 38]. Due to the central role of the gut micro-
biome in profoundly shaping the diversity of the
systemic bile pool, BA offer an intriguing and convincing
pathway for crosstalk between gut microbes and their
host. Interestingly, a study from the Bäckhed group ele-
gantly revealed that the altered bile profile observed in
germ-free mice may contribute to their altered metabol-
ism by affecting the gut microbiome [39]. This form of
two-way communication is relatively rare in
microbe-host dialogue. Sayin et al. [37] demonstrated
the importance of tauro-conjugated muricholic acids (i.e.
tauro-β-muricholic acid) as FXR antagonists in the mur-
ine system, while chenodeoxycholic acid (CDCA) dem-
onstrates the greatest agonistic efficacy [40, 41].
Activation of FXR receptors in turn regulates FGF-15/19
and CYP7A1 expression, with implications for several
metabolic pathways in the host hepatocytes including
those involved in cholesterol metabolism [42].
At a simplistic level, microbial-mediated BA modifica-
tion increases their hydrophobicity, thereby leading to
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decreased reabsorption and increased excretion of
cholesterol-rich BAs in the faeces [43]. Indeed, interven-
tion with Lactobacillus spp. in metabolically dysfunc-
tional rodents has previously been shown to increase
faecal BA excretion and ameliorate the lipid profile [44].
By reducing the reabsorption of BA and creating a low
transhepatic flux, there is an increase in CYP7A1 tran-
scription that leads to a reduction in hepatic LDL-C
levels as a result of their use in BA synthesis [45]. Both
Lb. reuteri APC 2587 and Lb. mucosae DPC 6426 exhib-
ited considerable effects on CDCA in porcine bile, in-
creasing the BA > 400-fold and > 350-fold, respectively.
However, in vivo these newly unconjugated BA become
open to further catabolism by strains expressing alter-
nate enzymes [46]. This suggests that both strains could
alter host bile in humans in a manner that would pro-
mote BA synthesis and cholesterol excretion. Interest-
ingly, although Lb. reuteri APC 2587 and Lb. mucosae
DPC 6426 both demonstrated significant activity against
both porcine and murine bile, neither proved capable of
reducing TcMCA levels. This could be in part explained
due to their respective porcine and bovine origins
(Additional file 1: Table S1), in which they would not be
exposed to murine BA.
Although the FXR-FGF15/19 axis is of central im-
portance in the effects of BAs on host lipid metabolism,
it should be noted that BA receptors have also been
shown to trigger cascades which directly impact on car-
diovascular function without necessarily regulating lipid
metabolism. There are several G-protein coupled re-
ceptors involved in the effects of BAs on host metabol-
ism, such as TGR5 and muscarinic receptors. TGR5 is
activated by lithocholic acid, TLCA, cholic acid (CA),
deoxycholic acid (DCA) and CDCA, all of which were
found to be significantly increased in porcine bile fol-
lowing incubation with either Lb. mucosae DPC 6426
or Lb. reuteri APC 2587, bar TLCA which was de-
creased. While TGR5 has been shown to impact dir-
ectly upon atherogenic inflammation though
cAMP-mediated secretion of NO [47] and inhibition of
macrophage NF-κB signalling [48], it has also been
shown to modulate glucagon-like peptide (GLP)-1 se-
cretion [49]. Crucially, recent evidence indicates that
increasing GLP-1 levels can have significant indirect
knock-on effects for enterocyte formation of
triglyceride-rich chylomicrons [50, 51], while also dir-
ectly eliciting hypotensive atrial natriuretic peptide re-
lease from cardiomyocytes [52].
We have, herein, identified two potential mecha-
nisms through which Lb. mucosae DPC 6426 may
confer cardio-protective effects upon its host (as sum-
marised in Fig. 4). These include one or more
bile-modifying enzymes and an EPS capable of immu-
nomodulatory action. Moreover, these data indicate
that Lb. mucosae DPC 6426 BSH may have a more
significant impact on human bile metabolism than
that of a rodent, as human bile bears greater resem-
blance to the GcBA-rich profile of porcine bile. This
in turn may have further implications for improving
human host CVD status, and suggests that BSH activ-
ity is perhaps not the main mechanism through
which Lb. mucosae DPC 6426 attenuates cholesterol
accumulation in the apo-E−/− murine model. Further-
more, we have shown that the complex heteropolysac-
charide produced by Lb. mucosae DPC 6426 can
interact with the host immune system in vitro to pro-
mote a largely anti-inflammatory tone and factors
which are important to endothelial function. Finally, we
have previously recorded increased faecal excretion of
cholesterol in the apo-E−/− murine model following Lb.
mucosae DPC 6426, suggesting that the EPS itself may
possess some intrinsic sterol-binding capacity. Indeed,
each of these strain-specific features may be central to the
previously reported cardio-protective attributes associated
with Lb. mucosae DPC 6426.
Fig. 4 Putative Mechanisms Through Which Lactobacillus mucosae
DPC 6426 May Exert Cardio-protective Effects. Black text indicates
results which are reported in the present study, while grey text
represents extrapolations of the potential in vivo effects of such
physiological reactions to Lactobacillus mucosae DPC 6426 and its
metabolites, in the context of cardiovascular disease. cBA,
conjugated bile acids; FXR, farnesoid X receptor; FGF15, fibroblast
growth factor 15; CHO, cholesterol; BSH, bile salt hydrolase; EPS,
exopolysaccharide; SEC, secretome; M1, classically activated
macrophage; M2, alternatively activated macrophage; IL-10,
interleukin-10; CD206, cluster of differentiation 206; NO, nitric oxide;
ROS, reactive oxygen species; DC, dendritic cell
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Conclusions
These data suggest that Lb. mucosae DPC 6426 has the
potential to act on host CVD status through a multitude
of pathways. Firstly, the microbe has been shown to ex-
press enzymes which shape host bile pool profile in a
manner that may promote endothelial function, while
also reducing systemic inflammation. This same attri-
bute may in turn alter BA metabolism and signalling in
a manner which has potential to improve host lipid and
cholesterol metabolism. However, due to the BA specifi-
city of the microbe, it is likely that these effects would
only be obvious in the glyco-conjugated BA-rich porcine
or human system. In addition, the EPS and secretome
produced by Lb. mucosae DPC 6426 appears to promote
a generally anti-inflammatory tone in vitro, which may
contribute to the attenuation of inflammatory-mediated
metabolic dysfunctions, if mirrored in vivo.
Materials & methods
Bacterial Strains & Culture Conditions
All Lb. mucosae strains used in this study - which include
DPC 6418, 6420, 6425 and 6426 - are of mammalian intes-
tinal origin and were obtained from the Teagasc Moorepark
Food Research Centre culture collection. Lb. reuteri APC
2587 is a bile salt hydrolase-active strain of human origin,
and was obtained from the APC Microbiome Institute cul-
ture collection. RAPD PCR was performed for all strains in
this study, using primer sequence 5’-GCTCGTATG
TTGTGTGG-3′ as described in Navidghasemizad et al.
[53], to ensure genetic uniqueness of closely related strains.
All strains were grown from − 80 °C stocks (75% glycerol)
on de Mann Rogosa Sharpe (MRS; Difco) media solidified
with 1.5% agar in gas jars with anaerobic gas packs (Anae-
rocult A, Merk KGaA, Darmstadt, Germany), at 37 °C for
48 h. Single colonies were subsequently grown overnight
and maintained in MRS broth for a maximum of three sub-
cultures prior to assays.
Exopolysaccharide Isolation & Secretome
EPS was isolated from Lb. mucosae DPC 6426 as per
López et al. [54]. Fresh culture was autolysed at 100 °C
for 15 min in a water bath (Grant, JB series). This sus-
pension was then centrifuged for 30 min at 3000 x g
(Sorvall RC5B Plus, rotor SLA3000). Supernatant was
collected and treated with 10% (v/v) 12M HCl for 5 min
at 70 °C, with overhead stirring. The solution was then
centrifuged again under the same conditions. Supernatant
was again collected and mixed with two volumes of
ice-cold ethanol. This mixture was left for 24 h at − 20 °C
with mild agitation. Precipitated carbohydrates were col-
lected by centrifugation and resuspended in a minimal
amount of ultrapure water. The ethanol precipitation step
was repeated twice more. The pelleted carbohydrate was
resuspended in minimal ultrapure water and dialyzed with
12–14 kDa MWCO dialysis tubing (Sigma Aldrich,
Ireland) against ultrapure water for three days at 4 °C with
twice daily water changes. This dialysed solution was then
lyophilized (VirTis Advantage Wizard 2.0).
As a secondary purification, the crude EPS was dis-
solved in 50 mM Tris–HCl, 10 mM MgSO4·7H2O, pH
7.5 at a final concentration of 5 mgml− 1 and treated
with DNAse type-I (Sigma Aldrich, Ireland, final con-
centration 2.5 μg ml− 1) for six hours at 37 °C. The solu-
tion was then treated with pronase E (Sigma Aldrich,
Ireland, final concentration 50 μg ml− 1, dissolved in 50
mM Tris–HCl, 2% EDTA, pH 7.5) for 18 h at 37 °C.
Trichloroacetic acid was then added (12% w/v, final con-
centration) and stirred at room temperature for 30 min,
followed by centrifugation. Resulting supernatant was
adjusted to pH 4.0–5.0 with 10M NaOH. It was then di-
alyzed against ultrapure water under the previous condi-
tions, followed by lyophilisation.
The secretome which was applied to macrophage in in
vitro components of the present study was composed
entirely of spent cell-free MRS broth in which Lb. mu-
cosae DPC 6426 had been cultured. It is anticipated that
this medium contains all the metabolites and enzymes
which the strain secretes externally under in vitro cul-
ture conditions. Following overnight incubation of the
bacteria in broth as previously described, the culture was
centrifuged at 22,000 x g for 15 min. The resulting
supernatant was passed through a 45 μm filter and
stored at − 20 °C prior to exposures.
RAW 264.7 macrophage Secretome & EPS exposures
Cell line & culture
The murine macrophage cell line RAW 264.7 (ATCC
TIB-71, LCG Systems) was maintained in Dulbecco’s
Modified Eagle Medium/Nutrient Mixture F-12/Gluta-
MAX™ (DMEM/F-12/GlutaMAX™; Gibco via Thermo
Fisher Scientific) supplemented with 10% heat –inacti-
vated foetal bovine serum (FBS; Sigma-Aldrich) in the
presence of 24 ng/ml gentamicin (Gibco via Thermo
Fisher Scientific). Experiments and cell culture mainten-
ance were performed at 37 °C in a humidified atmos-
phere containing 5% CO2.
Macrophage polarization
RAW 264.7 cells (1 × 105 cells) were seeded in 6-well cul-
ture plates and cultured as described above for 48 h. Fol-
lowing 12 h starvation in serum-free medium, control
samples for M1 or M2 polarization were stimulated with
either 10 ngml− 1 lipopolysaccharide (Sigma-Aldrich) and
50 ngml− 1 mouse IFN-γ (R&D Systems), or 20 ngml− 1
mouse IL-4 (R&D systems) for 24 h, respectively. Un-
stimulated RAW 264.7 cells were cultivated for 24 h and
then exposed to either the secretome of Lb. mucosae DPC
6426 or 10mgml− 1 of purified EPS isolated from the
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same strain, both suspended in supplemented medium
without the antibiotic for 24 h. After washing the samples
with supplemented medium, RAW 264.7 cells were har-
vested and stored at − 80 °C prior to qRT-PCR analysis.
Gene transcription in murine macrophage
Total RNA was extracted using RNeasy® (Qiagen) ac-
cording to the manufactures’ protocol. The RNA con-
centrations were determined by A260 measurements.
cDNA synthesis was performed using Tetro cDNA Syn-
thesis Kit (Bioline) with 5 μg RNA per 50 μl reaction, ac-
cording to manufactures’ instructions. RT-PCR was
performed with Lightcycler SYBR Green I MasterKit
(Roche Diagnostics Ltd.) and 0.25 mM of the following
primers: Tnf: 5’AAAT CGGC TGAC GGTG TGGG3’
and 5’CCCA CACC GTCA GCCG ATTT3’; iNos: 5’
CAGA GGAC CCAG AGAC AAGC3’ and 5’TGCT
GAAA CATT TCCT GTGC3’; Cd206: 5’CAGG TGTG
GGCT CAGG TAGT3’ and 5’TGTG GTGA GCTG
AAAG GTGA3’; Il-10: 5’GCTC TTAC TGAC TGGC
ATGAG3’ and 5’CGCA GCTC TAGG AGCA TGTG3’;
and Il-6: 5’CCAG TTGC CTTC TTGG GACT3’ and
5’GGTC TGTT GGGA GTGG TATCC3’. All PCR as-
says were set up in duplicate and analyzed using the
LightCycler 480 system (Roche Diagnostics Ltd.). PCR
conditions were set at 10 mins at 95 °C, followed by 50
cycles of 95 °C for 10 s, 60 °C for 5 s and 72 °C for 15 s.
18 s was used as the reference gene.
NO measurement and viability/metabolic activity assay
Cell line & culture
The macrophage cell line RAW 264.7 (ATCC TIB-71,
LCG Systems) was maintained in DMEM as mentioned
previously, but in the presence of 100 U/ml penicillin
and 100 μg/ml streptomycin (Sigma Aldrich) rather than
gentamicin. Cells were passaged twice weekly.
Macrophage stimulation
RAW 264.7 cells (1.5 × 105 cells) were seeded in a vol-
ume of 200 μl into 96-well culture plates and cultured as
described above, except that phenol red was omitted
from the medium. The stimulants (different concentra-
tions of EPS isolated from Lb. mucosae DPC 6426, with
or without the extra addition of 1 μg/ml LPS (Sigma-Al-
drich)) were added immediately to the macrophages.
After 24 h incubation, 75 μl of supernatant was har-
vested and stored at − 80 °C for subsequent measure-
ment of secreted cytokines. Another 75 μl of supernatant
was transferred to a new plate where NO production
was measured using the Griess assay and the remaining
culture supernatant and cells were used for a cell viabil-
ity assay.
Nitrite assay
Nitrite, a stable metabolite of NO, produced by activated
macrophages was measured by the Griess assay [55].
Briefly, an aliquot of 75 μl culture supernatant from each
well was transferred to the wells of a new flat-bottomed
96-well plate and combined with 100 μl of 1% sulfanila-
mide and 100 μl of 0.1% naphthylenediamine (both were
prepared in 2.5% phosphoric acid solution). After 5 min
incubation at room temperature, the nitrite concentra-
tion was determined by measuring optical density
(OD540, reference filter 690 nm) of each well using a
SPECTRA MAX microplate reader (Molecular Devices).
Sodium nitrite (Sigma Aldrich) was used as a standard
to determine nitrite concentrations in the cell-free
medium.
Viability/metabolic activity assay (XTT)
This assay provides a spectrophotometric method for es-
timating cell viability based on the mitochondrial activity
in living cells, as it measures the mitochondrial dehydro-
genase activity of living cells. The mitochondrial dehy-
drogenases of viable cells reduce the tetrazolium ring of
XTT (Sigma Aldrich), yielding an orange formazan de-
rivative, which is water-soluble. Briefly, 20% v/v of XTT
was added to the wells and the cells were incubated for
3–4 h at 37 °C in a humidified atmosphere containing
5% CO2. Subsequently, the amount of formazan deriva-
tive was determined by measuring optical density
(OD450, reference filter 690 nm) of each well using a
SPECTRA MAX microplate reader (Molecular Devices).
An increase or decrease in viable cells relative to control
cells, results in an accompanying change in the amount
of formazan formed.
Cytokine production by murine macrophages
To measure IL-10 and TNF-α production, the Ready-
Set-Go ELISA (Ebioscience) was used according to the
manufacturer’s instructions. Briefly, plates were coated at
room temperature for 3 h, after which the plates were
blocked for 2 h with blocking buffer. Standards and sam-
ples (10 x diluted for TNF-α) were added to the wells and
the plates incubated overnight at 4 °C. The following day,
the plates were washed by filling and emptying the wells
with PBS and then the biotin-conjugated antibody to
mouse IL-10 and TNF-α was added for 2 h at room
temperature. After washing the plates three times, strepta-
vidin conjugated to horse radish peroxidase was added
and incubated for 1 h at room temperature in the dark.
After another wash, substrate was added and after allow-
ing for proper colour development, the reaction was ter-
minated using 2M H2SO4. Finally, the optical density of
the reaction was measured (OD450, reference filter 570
nm) using the SPECTRA MAX microplate reader (Mo-
lecular Devices) and compared with the optical density of the
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known standard samples to determine cytokine
concentrations.
TLR reporter assay
Human embryonic kidney cells [56] (Invivogen) were
transformed with different human Toll like receptors
(TLR1/2 [293-mtlr1/2], TLR2 [293-mtlr2] and TLR4
[293-mtlr4]) and a NF-κB luciferase reporter construct
(Invivogen). Approximately 6 × 104 cells of each reporter
line in DMEM medium supplemented with 100 U/ml
penicillin and 100 μg/ml streptomycin (Sigma Aldrich)
and 10% fetal bovine serum (Invitrogen) were seeded
into wells of a black, clear bottom 96-well plate (Invitro-
gen) and incubated overnight at 37 °C in a humidified at-
mosphere containing 5% CO2. The cells were
subsequently stimulated with different concentrations of
EPS isolated from Lb. mucosae DPC 6426, PCSK (5 μg/
ml, Invitrogen), or different concentrations of LPS (Invi-
vogen) as positive controls or with medium alone (nega-
tive control) and incubated for 4 h at 37 °C in a CO2
incubator. After this incubation period, half of the
medium was replaced with ‘Bright Glow’ (Promega), the
plate was then vortexed for 5 min and the luminescence
measured using a Spectramax M5 (Molecular Devices).
HEK293 cells not expressing any of the TLR receptors
but harbouring pNIFTY, a luciferase reporter construct
for NF-κB activation (Invivogen, Toulouse, France) were
used to control for TLR-independent activation of
NF-κB.
Oxidative burst activity neutrophils
Cell line & culture
The human promyelocyte precursor cell line, HL60
(ATCC CCL-240, LCG Systems), was maintained in
RPMI medium supplemented with 10% FBS, 100 μg/ml
streptomycin, and 100 IU/ml penicillin (Sigma Aldrich)
at 37 °C in an atmosphere containing 5% CO2. Cell
count and viability were performed using a standard try-
pan blue cell counting technique. To differentiate the
cells into neutrophils, cells were grown to a density of
1 × 106 cells/ml with addition of 1.25% dimethyl sulfox-
ide for three to four days. After washing the cells and
re-suspending them in RPMI medium with 10% v/v fetal
bovine serum (FBS) supplemented with antibiotics, cells
displayed typical neutrophilic behaviour and adhered to
the plate in less than an hour.
Isolation of human neutrophils
Venous blood was drawn from healthy volunteers using
vacuette tubes (Greiner Bio-one), coated with lithium
heparin. Blood was carefully layered onto a Percoll (GE
healthcare) gradient of 1.079 and 1.098 density. After
centrifugation for 8 min at 150 x g (with minimal brake)
and additionally for 10 min at 1200 x g (without break),
the neutrophils were isolated as a single layer of cells.
After lysis of the erythrocytes, the cells were counted
and gently resuspended in RPMI medium without phe-
nol red.
Nitroblue tetrazolium assay
After 3/4 days of differentiation (HL60), or directly after
isolation (freshly isolated neutrophils), cells were seeded
at a density of 1.5 × 105 cells/well in RPMI medium
without phenol red. After allowing adherence for one
hour, plates were centrifuged for 5 min at 750 x g, after
which the culture supernatant was aspirated and
replaced by 153 μl of nitroblue tetrazolium (Sigma
Aldrich). Different concentrations of the isolated EPS (1,
5, 10, 50 and 100 μg/ml) were prepared from stock solu-
tion by serial dilution in serum-free RPMI medium and
17 μl was added to the nitroblue tetrazolium mixture.
For control samples, 17 μl of serum-free RPMI medium
was added. The cells were incubated for 90 min at 37 °C
in atmosphere containing 5% CO2. Following another
centrifugation step under the conditions previously men-
tioned, the nitroblue tetrazolium was aspirated and the
cells fixated with 100 μl methanol for 7 min at room
temperature. After aspiration of the methanol, the plates
were allowed to air dry for 15 min. Finally, 120 μl of
KOH and 140 μl of DMSO was added to the plate and
thoroughly mixed to completely dissolve the formazan
crystals formed by the cells. The amount of formazan
derivative was then determined by measuring optical
density (OD620, reference filter 414 nm) of each well
using a SPECTRA MAX microplate reader (Molecular
Devices).
Bile acid metabolism
Bile salt hydrolase plate assay
The ability to deconjugate BAs was determined qualita-
tively as previously described [57]. Strains were grown
under the conditions outlined above at 37 °C for 18 h in
MRSthio broth, and 5 μl of this culture was then spotted
onto MRSthio plates containing 0.037% w/v CaCl2 and
0.5% w/v either TDCA or GDCA (Sigma Aldrich). Plates
were incubated under the conditions described above at
37 °C for 24 h before inspection and BSH activity was
deemed present in a strain if a halo was visible sur-
rounding the colony cell mass.
Cell-free protein extract preparation
Extracts were prepared from each strain as per the
method of Jarocki et al. [58]. Briefly, cultures were
grown to stationary phase in 200ml MRS broth and cen-
trifuged at 10,000 x g for 10 min at 4 °C. Pelleted cells
were washed twice with PBS (Sigma Aldrich) before be-
ing resuspended in 8ml of PBS with 10mM
2-mercaptoethanol (Sigma Aldrich). Cell suspensions
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were then sonicated on wet ice for 3 min followed by
centrifugation at 20,000 x g for 10 min at 4 °C. The
resulting supernatants were stored at − 20 °C prior to
assay. The protein content of all extracts was quantified
by the Bradford method [59], with bovine serum albu-
min (Sigma Aldrich) as standard.
Bile salt hydrolase activity assay
The extracts were diluted to a protein concentration of
approximately 0.5 mgml− 1 in PBS 2-mercaptoethanol
and 100 μl of this solution was mixed with 100 μl 20 mM
TDCA or GDCA in the same buffer. This suspension
was incubated at 37 °C for 30 min, at which point the re-
action was terminated by the addition of 200 μl 15% (w/
v) trichloroacetic acid (Sigma Aldrich). All proteins were
then precipitated out of solution by centrifugation at
14,000 x g. The amounts of free amino acids (taurine
and glycine) were quantified using a Jeol JLC-500 V AA
analyser in conjunction with a Jeol Na+ high perform-
ance cation exchange column (Jeol Ltd., Tokyo, Japan).
One unit of BSH activity is defined as nmol of amino
acid cleaved from the relevant BA per mg of protein and
expressed per minute (Umin− 1).
Bile deconjugation profiling
The specificity and BA preference of the BSH expressed
by Lb. mucosae DPC 6426 and by Lb. reuteri APC 2587
were assessed in both porcine and murine bile. Fresh
overnight cultures were sub-cultured into MRS broth
supplemented with 0.5% of either porcine or murine gall
bladder bile. Samples were prepared and analysed for
BA profile by the adjusted UPLC-MS method of Swann
et al. [60], described previously in Joyce et al. [10].
Statistical analysis
All RT-PCR cell culture experiments were conducted
three times with duplicate samples. BSH-activity and in-
dividual bile fluctuations in bile deconjugation profiling
results were analysed by one-way ANOVA with a Bon-
ferroni correction for multiple comparisons. For all stat-
istical tests, differences between means were considered
significant if the P value was < 0.05.
Additional file
Additional file 1: Document Contains Information on Bacterial Strain
Origins, as well as Data on Neutrophil Reactive Oxygen Species Assays
and Bile Deconjugation Profiles. Figure S1. Relative Oxidative Burst
Activity Of Differentiated HL-60 Human Neutrophils and Freshly Isolated
Human Neutrophils. Neutrophils were stimulated for 90 min with or
without additional PMA stimulation after which reactive oxygen species
production was measured. Experiments were often repeated and are
depicted as reactive oxygen production relative to medium control (A;
HL-60 cells, C; freshly isolated neutrophils) or relative to PMA (1 ng.ml− 1)
stimulated samples (B; HL-60 cells, D; freshly isolated neutrophils from
two donors). Data are shown as average ± SD. Differences were
considered statistically significant when p < 0.05 (*), p < 0.01 (**) or p <
0.001 (***).
Table S1. Origins of Strains. Table S2. Full Bile Deconjugation
Experiment Profile. Full quantitative list of bile acids in MRS
supplemented with murine or porcine bile untreated, or cultured with
APC 2587 or DPC 6426. Data represent the means of duplicate
experiments for untreated bile, and triplicates for cultured bile. Means
with the * postfix are significantly different (p < 0.05) from the untreated
bile concentration, as assessed by one-way ANOVA. (DOCX 115 kb)
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